FRANCISCO DE ASIS AYALA DE LA PEÑA

Garcia-Torralba E, Perez Ramos M, Ivars Rubio A, Navarro Manzano E, Blaya Boluda N, Lloret Gil M, Aller A, de la Morena Barrio P, Garcia Garre E, Martinez Diaz F, Garcia Molina F, Chaves Benito A, Garcia-Martinez E, Ayala de la Pena F. Deconstructing neutrophil to lymphocyte ratio (NLR) in early breast cancer: lack of prognostic utility and biological correlates across tumor subtypes. Breast Cancer Res Treat. 2024 Mar 7. doi: 10.1007/s10549-024-07286-x. Online ahead of print. PubMed PMID: 38453782.

AÑO: 2024; IF: 3.8

38453782

Rodenas MC, Penas-Martinez J, Pardo-Sanchez I, Zaragoza-Huesca D, Ortega-Sabater C, Pena-Garcia J, Espin S, Ricote G, Montenegro S, Ayala-De La Pena F, Luengo-Gil G, Nieto A, Garcia-Molina F, Vicente V, Bernardi F, Lozano ML, Mulero V, Perez-Sanchez H, Carmona-Bayonas A, Martinez-Martinez I. Venetoclax is a potent hepsin inhibitor that reduces the metastatic and prothrombotic phenotypes of hepsin-expressing colorectal cancer cells. Front Mol Biosci. 2023 May 19;10:1182925. doi: 10.3389/fmolb.2023.1182925. eCollection 2023. PubMed PMID: 37275957; PubMed Central PMCID: PMC10235687.

AÑO: 2023; IF: 5.0

37275957

Vera R, Juan-Vidal O, Safont-Aguilera MJ, de la Pena FA, Del Alba AG. Sex differences in the diagnosis, treatment and prognosis of cancer: the rationale for an individualised approach. Clin Transl Oncol. 2023 Jul;25(7):2069-2076. doi: 10.1007/s12094-023-03112-w. Epub 2023 Feb 18. PubMed PMID: 36802013; PubMed Central PMCID: PMC10250517.

AÑO: 2023; IF: 3.4

36802013

Sanchez-Canovas M, Jimenez-Fonseca P, Fernandez Garay D, Cejuela Solis M, Casado Elia D, Coma Salvans E, de la Haba Vacas I, Gomez Sanchez D, Fernandez Montes A, Morales Gimenez R, Biosca Gomez de Tejada M, Arrazubi Arrula V, Sequero Lopez S, Otero Candelera R, Sanchez Cendra C, Justo de la Pena M, Moreno Munoz D, Orillo Sarmiento M, Martinez de Castro E, Garcia Escobar I, Bernal Vidal A, Ortega Moran L, Munoz Martin AJ, Sanchez Bayona R, Martinez Ortiz MJ, Ayala de la Pena F, Vicente V, Carmona-Bayonas A. Prediction of serious complications in patients with pulmonary thromboembolism and solid cancer: Validation of the EPIPHANY Index in a prospective cohort of patients from the PERSEO study. PLoS One. 2023 May 9;18(5):e0266305. doi: 10.1371/journal.pone.0266305. eCollection 2023. PubMed PMID: 37159465; PubMed Central PMCID: PMC10168567.

AÑO: 2023; IF: 3.7

37159465

Garcia-Torralba E, Navarro Manzano E, Luengo-Gil G, De la Morena Barrio P, Chaves Benito A, Perez-Ramos M, Alvarez-Abril B, Ivars Rubio A, Garcia-Garre E, Ayala de la Pena F, Garcia-Martinez E. A new prognostic model including immune biomarkers, genomic proliferation tumor markers (AURKA and MYBL2) and clinical-pathological features optimizes prognosis in neoadjuvant breast cancer patients. Front Oncol. 2023 May 29;13:1182725. doi: 10.3389/fonc.2023.1182725. eCollection 2023. PubMed PMID: 37313470; PubMed Central PMCID: PMC10258327.

AÑO: 2023; IF: 4.7

37313470